Has Anyone Got Thyroid Cancer From Zepbound? Clinical Evidence

Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management that carries a Boxed Warning regarding thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning stems from animal studies showing tumor development in rodents, though as of 2024, no confirmed cases of thyroid cancer have been directly attributed to Zepbound in humans. The medication is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Understanding this theoretical risk and discussing thyroid history with healthcare providers is essential before starting treatment.

We offer compounded medications and Zepbound®. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. References to Wegovy®, Ozempic®, Rybelsus®, Mounjaro®, or Saxenda®, or other GLP-1 brands, are informational only. Compounded and FDA-approved medications are not interchangeable.

Understanding Zepbound and Thyroid Cancer Risk

Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with weight-related comorbidities. While Zepbound has demonstrated significant efficacy in clinical trials, it carries a Boxed Warning regarding the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).

This warning stems from preclinical studies in rodents, where tirzepatide and other GLP-1 receptor agonists caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. Thyroid C-cells produce calcitonin, and GLP-1 receptors are present on these cells in rodents. Chronic stimulation of these receptors led to C-cell hyperplasia and tumor formation in animal models.

As of 2024, there are no confirmed cases of thyroid cancer directly attributed to Zepbound in humans. However, the FDA states that it is unknown whether Zepbound causes thyroid C-cell tumors, including MTC, in humans. The relevance of rodent C-cell tumor findings to human risk remains uncertain, as available data suggest humans have different GLP-1 receptor expression patterns compared to rodents. The FDA requires this warning due to the serious nature of medullary thyroid carcinoma and the biological plausibility of the mechanism. Patients considering Zepbound should understand this theoretical risk and discuss their personal and family thyroid history with their healthcare provider before initiating treatment.

Clinical Evidence: Thyroid Tumors in Zepbound Studies

The clinical development program for tirzepatide included extensive safety monitoring across multiple large-scale trials, including the SURMOUNT and SURPASS series. These studies enrolled thousands of participants and followed them for periods ranging from 40 to 72 weeks. Throughout these trials, investigators specifically monitored for thyroid adverse events, including thyroid neoplasms.

According to the FDA review of clinical trial data, no cases of medullary thyroid carcinoma were reported in patients treated with tirzepatide. Thyroid-related adverse events were uncommon in the clinical trials. However, it's important to note that these trials were not specifically powered to detect rare outcomes like MTC.

The duration of human clinical trials (typically 1-2 years) may be insufficient to detect slowly developing tumors like MTC, which can take years or decades to manifest clinically. The median time from initial genetic mutation to MTC diagnosis in hereditary cases can exceed 20 years. Additionally, MTC is a rare cancer, with an annual incidence of approximately 0.2 cases per 100,000 people in the United States according to SEER data, making it statistically challenging to detect small increases in risk even in large clinical trial populations.

Post-marketing surveillance continues to monitor for thyroid malignancies in real-world populations using Zepbound. Healthcare providers are encouraged to report any cases of thyroid cancer in patients treated with tirzepatide to the FDA's MedWatch program (www.fda.gov/medwatch) to enhance our understanding of this potential risk.

FDA Boxed Warning for Thyroid C-Cell Tumors

The FDA-approved prescribing information for Zepbound contains a Boxed Warning—the most serious type of warning—regarding thyroid C-cell tumors. This warning states that tirzepatide causes thyroid C-cell tumors at clinically relevant exposures in rodents and that it is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.

The Boxed Warning specifically advises that Zepbound is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a hereditary condition that significantly increases MTC risk. This contraindication is absolute, meaning these patients should not receive Zepbound under any circumstances due to the theoretical but potentially serious risk.

The warning reflects the FDA's precautionary approach when animal data suggest a serious potential risk, even in the absence of confirmed human cases. Similar warnings exist for other GLP-1 receptor agonists, including liraglutide (Saxenda) and semaglutide (Wegovy), which share the same mechanism of action and demonstrated similar findings in rodent studies.

Healthcare providers prescribing Zepbound should counsel patients about this warning and provide the FDA-approved Medication Guide. Patients should be informed about symptoms of thyroid tumors, including a neck mass, dysphagia (difficulty swallowing), dyspnea (shortness of breath), or persistent hoarseness. While the absolute risk in humans remains uncertain and likely very low, the severity of MTC—which can be aggressive and difficult to treat—justifies this prominent safety communication.

Who Should Not Take Zepbound Due to Thyroid Concerns

Zepbound is absolutely contraindicated in specific patient populations due to thyroid cancer concerns. Patients with a personal history of medullary thyroid carcinoma should never use Zepbound, as the theoretical risk of tumor recurrence or progression cannot be excluded. Even patients with successfully treated MTC remain at risk for recurrence, and any medication that might stimulate C-cell activity should be avoided.

Patients with a family history of MTC (any degree of relation) should not receive Zepbound. Approximately 25% of MTC cases are hereditary, often associated with genetic mutations in the RET proto-oncogene. Family history suggests possible hereditary predisposition, even if genetic testing has not been performed.

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is an absolute contraindication to Zepbound use. MEN 2 is an inherited disorder characterized by MTC (occurring in nearly 100% of affected individuals), pheochromocytoma, and parathyroid abnormalities. Patients with known MEN 2 or those with genetic mutations associated with MEN 2 (particularly RET mutations) must avoid all GLP-1 receptor agonists.

Additionally, patients with unexplained thyroid nodules or elevated calcitonin levels should undergo thorough evaluation before considering Zepbound. Baseline serum calcitonin measurement is not routinely recommended for all patients, as its utility in screening is controversial due to low specificity. However, if calcitonin testing is performed and levels are elevated, further investigation with thyroid ultrasound and possible fine-needle aspiration biopsy should be completed before initiating therapy. Patients with suspected hereditary MTC or MEN2 should be referred to endocrinology and/or genetics specialists. Patients should discuss their complete medical and family history with their healthcare provider to determine if Zepbound is appropriate for their individual situation.

Monitoring and Safety Precautions While Using Zepbound

While routine calcitonin monitoring or thyroid ultrasound is not required or recommended for patients taking Zepbound, as noted in the FDA prescribing information, healthcare providers and patients should remain vigilant for signs and symptoms of thyroid tumors. Patients should be counseled to report any neck mass, persistent hoarseness, dysphagia, or dyspnea immediately, as these may indicate thyroid pathology requiring urgent evaluation.

If a thyroid nodule is detected during Zepbound therapy, appropriate diagnostic workup should include thyroid ultrasound to characterize the nodule's features. Suspicious characteristics (hypoechoic appearance, irregular margins, microcalcifications, increased vascularity) warrant further evaluation with fine-needle aspiration biopsy, according to American Thyroid Association guidelines. If calcitonin is measured and markedly elevated (e.g., >50 pg/mL), referral to an endocrinologist or thyroid specialist is appropriate.

Patients with pre-existing thyroid disease (such as hypothyroidism or benign nodular thyroid disease) are not contraindicated from using Zepbound, but should maintain regular follow-up with their healthcare provider. Any changes in thyroid function or nodule characteristics should be evaluated appropriately. Thyroid function tests (TSH, free T4) should be monitored according to standard clinical practice for the underlying thyroid condition, not specifically because of Zepbound use.

Patient education is essential for safety. Individuals taking Zepbound should understand the warning signs of thyroid tumors and know when to seek medical attention. They should inform all healthcare providers about their Zepbound use, particularly if thyroid evaluation becomes necessary for any reason. Patients should not discontinue Zepbound without consulting their prescribing physician, but should promptly report any concerning symptoms. Healthcare providers should counsel patients about the Boxed Warning, provide the FDA Medication Guide, and document according to standard practice.

Frequently Asked Questions